BioPharma Dive - Latest News

Gilead leans on HIV drugs as oncology sales slow

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for Trodelvy and its cancer cell therapies.

Apr 25, 2025 - 17:20
 0
Gilead leans on HIV drugs as oncology sales slow

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for Trodelvy and its cancer cell therapies.

Read More

Tags:

Previous Article

Study illustrates pros, cons in AI readings of 3D mammography scans

Next Article

Armani celebrates 20 Years of Privé with an exhibition in Milan

Related Posts

Cargo shelves cell therapy research and lays off almost all staff

Cargo shelves cell therapy research and lays off almost...

Mar 19, 2025  0

Merck opens $1B vaccine plant in North Carolina

Merck opens $1B vaccine plant in North Carolina

Mar 11, 2025  0

In FDA job cuts, experts see threat of far-reaching impact

In FDA job cuts, experts see threat of far-reaching impact

Feb 20, 2025  0